Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000002 | 0.93 | HPGD (0.47) | EPHX2KCNH2MLYCDPIK3CALMNA | |
| SCHEMBL2006557 | 0.87 | GAA (0.39) | EPHX2KCNH2SMN1; SMN2PIK3CALMNA | |
| SCHEMBL2004287 | 0.87 | NPC1 (0.40) | KCNH2SMN1; SMN2PIK3CALMNAHPGD | |
| SCHEMBL2002032 | 0.83 | HSD11B1 (0.35) | SMN1; SMN2PIK3CAHPGDPOLBRORC | |
| SCHEMBL2008902 | 0.82 | CPT1A (0.35) | ALOX5APFEN1SMN1; SMN2PIK3CAPOLB | |
| SCHEMBL2004171 | 0.80 | EPHX2 (0.47) | EPHX2KCNH2MLYCDHPGDSLC6A9 | |
| SCHEMBL2001814 | 0.79 | CNR1 (0.40) | SMN1; SMN2PIK3CAPOLBRORCALDH1A1 | |
| SCHEMBL2005665 | 0.79 | HTT (0.37) | SMN1; SMN2PIK3CALMNARORCALDH1A1 | |
| SCHEMBL2001763 | 0.79 | CNR2 (0.34) | KCNH2PIK3CALMNASCN9APOLB | |
| SCHEMBL1999329 | 0.79 | RORC (0.36) | EPHX2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | EPHX2 345/4885KCNH2 1073/4885ALOX5AP 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.